drugset
drugset / Trial / NCT03111069

Study of Doxorubicin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Intraoperative Brachytherapy for Unresectable or Refractory Pelvic and Abdominal Rhabdomyosarcoma and Undifferentiated Sarcomas in Children

NCT03111069 ↗

Phase 1 Withdrawn M.D. Anderson Cancer Center
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to find the highest tolerable dose of heated doxorubicin that can be given to patients during surgery with abdominal tumors. The safety of this drug will also be studied.

Timeline

Start
2018-08
Primary completion
2021-08
Completion
2021-08

Outcome

Outcome not reported

Stopped: “PI withdrew study”

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxorubicin Other / unclassified 0.015 mg/ml —

Indications

rhabdomyosarcoma